Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2008-04-16
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00659074
- Locations
- π¨π¦
Algorithme Pharma, Laval, Quebec, Canada
Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2008-04-16
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00659685
- Locations
- π¨π¦
Algorithme Pharma, Laval, Quebec, Canada
Bioavailability Study of Torsemide Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00653549
Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00653458
Bioavailability Study of Torsemide Tablets Under Fed Conditions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00654043
Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00654277
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fed Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00652730
- Locations
- π¨π¦
Phoenix International Life Sciences inc, St-Laurent, Quebec, Canada
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fed Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00652873
- Locations
- π¨π¦
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Bioavailability Study of Leflunomide Tablets Under Fed Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fed Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00653003
Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine the Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00652886
- Locations
- πΊπΈ
Gateway Medical Research, Inc, St.Charles, Missouri, United States
Β© Copyright 2025. All Rights Reserved by MedPath